Automated next-generation profiling of genomic alterations in human cancers
暂无分享,去创建一个
David R. Riley | Derrick E. Wood | Samuel V. Angiuoli | V. Velculescu | G. Cerqueira | Siân Jones | S. McCall | J. White | M. Datto | A. Zingone | E. Papp | M. Sausen | B. Ryan | A. McElhinny | James Hernandez | K. Deak | Paul M. McGregor | L. Diaz | J. Simmons | J. L. Prescott | A. Greer | L. Keefer | Kelly Gerding | Kenneth C. Valkenburg | Christopher Gault | Christine M Vollmer | J. F. Thompson | Jennifer Dickey | Kelly M. Gerding | K. Valkenburg
[1] Brett J. Kennedy,et al. Abstract 5671: Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project , 2020 .
[2] S. Baylin,et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer , 2020, Nature Cancer.
[3] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[4] David R. Riley,et al. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade , 2019, Clinical Cancer Research.
[5] Qin Li,et al. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy , 2019, Journal of Hematology & Oncology.
[6] M. Arcila,et al. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[7] Olaf Neumann,et al. Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis , 2018, International journal of cancer.
[8] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] J. Deleuze,et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer , 2018, Front. Oncol..
[10] Olaf Neumann,et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. , 2018, Translational lung cancer research.
[11] J. Lunceford,et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.
[12] P. Hofman,et al. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? , 2018, Translational lung cancer research.
[13] Rachel Karchin,et al. A machine learning approach for somatic mutation discovery , 2018, Science Translational Medicine.
[14] Christopher T. Saunders,et al. Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.
[15] Isabelle Salmon,et al. Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.
[16] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[17] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[18] Li Ding,et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.
[19] Mounir A. Ajam. Gaps and Opportunities , 2018 .
[20] A. Vadas. Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game BY ALEX VADAS , 2018 .
[21] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[22] Woo Yong Lee,et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples , 2017, Nature Communications.
[23] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.
[24] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[25] D J Mooney,et al. Tough adhesives for diverse wet surfaces , 2017, Science.
[26] R. Pe Benito,et al. Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities , 2017, Clinical lung cancer.
[27] Jay Shendure,et al. Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.
[28] Nikhil Wagle,et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.
[29] A. McGuire,et al. Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel , 2016, Applied & translational genomics.
[30] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[31] L. Clipson,et al. Improved Detection of Microsatellite Instability in Early Colorectal Lesions , 2015, PloS one.
[32] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[33] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[34] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[35] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[36] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[37] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[38] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[39] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[40] G. Parmigiani,et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.
[41] Xuhua Xia,et al. Position Weight Matrix, Gibbs Sampler, and the Associated Significance Tests in Motif Characterization and Prediction , 2012, Scientifica.
[42] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[43] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.
[44] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[45] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[46] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.
[47] M. Warmuth,et al. Targeted Cancer Therapies in the Twenty‐First Century: Lessons From Imatinib , 2010, Clinical pharmacology and therapeutics.
[48] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] A. Duval,et al. Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.
[50] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[51] K. Sirotkin,et al. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.
[52] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.